Keystone eSymposia Logo

Precision Oncology: Translating Discovery to the Clinic

June 21-24, 2021 | 9:00AM EDT | 1:00PM UTC | 3:00PM CEST*
*Program is in development and subject to change


Reset

Advanced Filters
Welcoming Remarks and Keynote Address
09:00am - 09:40am Eastern - June 21, 2021
Klaus P. Hoeflich, PhD, Chair, Nested Bio
Track: Welcoming Remarks and Keynote Address

Monday
Lineage Plasticity: Lessons from Prostate Cancer
09:00am - 09:40am Eastern - June 21, 2021
Charles L. Sawyers, MD, Johns Hopkins University School of Medicine
Track: Welcoming Remarks and Keynote Address

Clinical Genomics
09:40am - 10:55am Eastern - June 21, 2021
Scott W. Lowe, PhD, Co-Chair, Memorial Sloan Kettering Cancer Center; Todd R. Golub, MD, Co-Chair, Broad Institute
Track: Clinical Genomics

Monday
Pre-Clinical Approaches to Cancer Precision Medicine
09:40am - 10:05am Eastern - June 21, 2021
Todd R. Golub, MD, Broad Institute
Track: Clinical Genomics

Monday
Leukemia Genomics
10:05am - 10:30am Eastern - June 21, 2021
Elli Papaemmanuil, PhD, Memorial Sloan Kettering Cancer Center
Track: Clinical Genomics

Monday
Personalized Genomic Testing in Pediatric Oncology
10:30am - 10:55am Eastern - June 21, 2021
Jaclyn A. Biegel, PhD, Children's Hospital Los Angeles and Keck School of Medicine of USC
Track: Clinical Genomics

Targeting Novel Mechanisms
11:15am - 01:00pm Eastern - June 21, 2021
Todd R. Golub, MD, Co-Chair, Broad Institute; Scott W. Lowe, PhD, Co-Chair, Memorial Sloan Kettering Cancer Center
Track: Targeting Novel Mechanisms

Monday
LKB1/STK11 Axis in Precision Immunotherapy
11:15am - 11:40am Eastern - June 21, 2021
John V. Heymach, MD, PhD, University of Texas MD Anderson Cancer Center
Track: Targeting Novel Mechanisms

Monday
Structural Basis for the Action of Clinical MEK Inhibitors at KSR-Bound MEK
11:40am - 12:05pm Eastern - June 21, 2021
Arvin C. Dar, PhD, Icahn School of Medicine at Mount Sinai
Track: Targeting Novel Mechanisms

Monday
Non-Cell Autonomous Tumor Control via Senescence
12:05pm - 12:30pm Eastern - June 21, 2021
Scott W. Lowe, PhD, Memorial Sloan Kettering Cancer Center
Track: Targeting Novel Mechanisms

Monday
Short Talk: SCD1-Regulated Ferroptosis as a Novel Therapeutic Strategy in Non-Small Cell Lung Cancer
12:45pm - 01:00pm Eastern - June 21, 2021
Triparna Sen, PhD, Memorial Sloan Kettering Cancer Center
Track: Targeting Novel Mechanisms

Emerging Technologies I
09:00am - 11:10am Eastern - June 22, 2021
Alice T. Shaw, MD, PhD, Co-Chair, Novartis Institutes for Biomedical Research, Inc.; Nicola Aceto, PhD, Co-Chair, ETH Zürich
Track: Emerging Technologies I

Tuesday
Harnessing Tumor Evolution and Immune Responses to Treat Lung Cancer
09:00am - 09:25am Eastern - June 22, 2021
Valsamo Anagnostou, MD, Johns Hopkins University School of Medicine
Track: Emerging Technologies I

Tuesday
Single Cell Genomics Technologies in the Clinic – Challenges and Opportunities
09:25am - 09:50am Eastern - June 22, 2021
Gromoslaw A. Smolen, PhD, Celsius Therapeutics
Track: Emerging Technologies I

Tuesday
Biology and Vulnerabilities of Circulating Tumor Cells
09:50am - 10:15am Eastern - June 22, 2021
Nicola Aceto, PhD, ETH Zürich
Track: Emerging Technologies I

Tuesday
Structure and Function of Mammalian SWI/SNF Chromatin Remodeling Complexes in Human Cancer
10:15am - 10:40am Eastern - June 22, 2021
Cigall Kadoch, PhD, Dana-Farber Cancer Institute, Harvard Medical School
Track: Emerging Technologies I

Tuesday
Short Talk: Nano-Targeted Kinase Inhibitor Treatment of KRAS Mutant Lung Cancer
10:40am - 10:55am Eastern - June 22, 2021
Ramya Sridharan, BS, Weill Cornell Medical
Track: Emerging Technologies I

Tuesday
Short Talk: A Metastasis Map of Human Cancer Cell Lines
10:55am - 11:10am Eastern - June 22, 2021
Xin Jin, BS, Broad Institute of MIT and Harvard
Track: Emerging Technologies I

Clinical Trials and Overcoming Resistance
11:20am - 01:00pm Eastern - June 22, 2021
Nicola Aceto, PhD, Co-Chair, ETH Zürich; Alice T. Shaw, MD, PhD, Co-Chair, Novartis Institutes for Biomedical Research, Inc.
Track: Clinical Trials and Overcoming Resistance

Tuesday
Resistance to Non-Small Cell Lung Cancer Therapies
11:20am - 11:45am Eastern - June 22, 2021
Alice T. Shaw, MD, PhD, Novartis Institutes for Biomedical Research, Inc.
Track: Clinical Trials and Overcoming Resistance

Tuesday
Targeted EGFR/HER2 Therapy to Overcome the Blood-Brain Barrier
11:45am - 12:10pm Eastern - June 22, 2021
Lori Friedman, PhD, ORIC Pharmaceuticals
Track: Clinical Trials and Overcoming Resistance

Tuesday
Defining Mechanisms of Resistance to KRASG12C Inhibitors
12:10pm - 12:35pm Eastern - June 22, 2021
Jessica J. Lin, MD, Massachusetts General Hospital
Track: Clinical Trials and Overcoming Resistance

Tuesday
Mechanisms of Resistance to Endocrine Therapy and CDK4/6 Inhibitors in ER+ Breast Cancer
12:35pm - 01:00pm Eastern - June 22, 2021
Nikhil Wagle, MD, Dana-Farber Cancer Institute
Track: Clinical Trials and Overcoming Resistance

Tuesday
Meet the Editors Roundtable
02:00pm - 03:00pm Eastern - June 22, 2021
Sarah Hamilton, PhD, Cell Reports Medicine; Miguel Foronda, PhD, Nature Cancer; Avital Lev, PhD, Cancer Discovery; Lise Roth, PhD, EMBO Press
Track: Keystone Symposia Roundtables

Emerging Technologies II
09:00am - 10:55am Eastern - June 23, 2021
Jason S. Carroll, PhD, Co-Chair, Cancer Research UK, University of Cambridge; Russell W. Jenkins, MD, PhD, Co-Chair, Massachusetts General Hospital
Track: Emerging Technologies II

Wednesday
Driving Precision Medicine through Clinical Computational Oncology
09:00am - 09:25am Eastern - June 23, 2021
Priti Hegde, PhD, Foundation Medicine
Track: Emerging Technologies II

Wednesday
Organotypic Modeling of Cancer and Immune Cell Dynamics
09:25am - 09:50am Eastern - June 23, 2021
Russell W. Jenkins, MD, PhD, Massachusetts General Hospital
Track: Emerging Technologies II

Wednesday
Inferring and Making Sense Out of Cancer Cell Phylogenies
09:50am - 10:15am Eastern - June 23, 2021
Nir Yosef, PhD, University of California, Berkeley
Track: Emerging Technologies II

Wednesday
Targeted Protein Degradation- A New Approach for Challenging Targets
10:15am - 10:40am Eastern - June 23, 2021
Nathanael Gray, PhD, Stanford University
Track: Emerging Technologies II

Wednesday
Short Talk: MLL-Menin Inhibition Reverses Pre-leukemic Progenitor Self-renewal in NPM1 Mutant AML
10:40am - 10:55am Eastern - June 23, 2021
Hannah Julia Uckelmann, PhD, Dana-Farber Cancer Institute
Track: Emerging Technologies II

Targeting Gene Transcription
11:10am - 01:15pm Eastern - June 23, 2021
Russell W. Jenkins, MD, PhD, Co-Chair, Massachusetts General Hospital; Jason S. Carroll, PhD, Co-Chair, Cancer Research UK, University of Cambridge
Track: Targeting Gene Transcription

Wednesday
New Synthetic Lethal Interactions in Acute Myeloid Leukemia
11:10am - 11:35am Eastern - June 23, 2021
Christopher Vakoc, MD, PhD, Cold Spring Harbor Laboratory
Track: Targeting Gene Transcription

Wednesday
Proteomic Analysis of Chromatin Remodeling Complexes
11:35am - 12:00pm Eastern - June 23, 2021
Jason S. Carroll, PhD, Cancer Research UK, University of Cambridge
Track: Targeting Gene Transcription

Wednesday
Using GEMMs to Identify Therapeutic Vulnerabilities in MYC-Driven Small Cell Lung Cancer
12:00pm - 12:25pm Eastern - June 23, 2021
Trudy G. Oliver, PhD, Huntsman Cancer Institute
Track: Targeting Gene Transcription

Wednesday
Targeting the MLL Complex to Control Gene Expression
12:25pm - 12:50pm Eastern - June 23, 2021
Scott A. Armstrong, MD, PhD, Dana-Farber Cancer Institute
Track: Targeting Gene Transcription

Wednesday
PRMT1: A Novel Dependency at the Nexus of RNA Metabolism and Cancer
12:50pm - 01:15pm Eastern - June 23, 2021
Timothy Heffernan, PhD, MD Anderson Cancer Center
Track: Targeting Gene Transcription

Novel Therapeutics
09:00am - 11:10am Eastern - June 24, 2021
Scott W. Lowe, PhD, Co-Chair, Memorial Sloan Kettering Cancer Center; Klaus P. Hoeflich, PhD, Co-Chair, Nested Bio
Track: Novel Therapeutics

Thursday
Mechanisms of Resistance to Combined Inhibition of RAS Signaling plus Autophagy in Pancreatic Cancer
09:00am - 09:25am Eastern - June 24, 2021
Martin McMahon, PhD, University of Utah School of Medicine
Track: Novel Therapeutics

Thursday
Targeting Protein Kinases in Cancer
09:25am - 09:50am Eastern - June 24, 2021
Track: Novel Therapeutics

Thursday
A General Allele-Specific Model for Understanding and Treating Tumors Driven by ERK-Activation
09:50am - 10:15am Eastern - June 24, 2021
Neal Rosen, MD, PhD, Memorial Sloan-Kettering Cancer Center
Track: Novel Therapeutics

Thursday
High Dose Vitamin C and Inactivation of DNA Repair Boost Cancer Immunotherapy
10:15am - 10:40am Eastern - June 24, 2021
Alberto Bardelli, PhD, University of Torino
Track: Novel Therapeutics

Thursday
Short Talk: Regulation of PTEN Translation by PI3K Signaling Maintains Pathway Homeostasis
10:40am - 10:55am Eastern - June 24, 2021
Radha Mukherjee, PhD, Memorial Sloan Kettering
Track: Novel Therapeutics

Thursday
Short Talk: Oncogenic CCNE1 Amplification Is Synthetic Lethal with PKMYT1 Kinase Inhibition
10:55am - 11:10am Eastern - June 24, 2021
Jordan Young, PhD, Repare Therapeutics, Canada
Track: Novel Therapeutics

The Future of Precision Oncology
11:35am - 12:25pm Eastern - June 24, 2021
Klaus P. Hoeflich, PhD, Co-Chair, Nested Bio; Scott W. Lowe, PhD, Co-Chair, Memorial Sloan Kettering Cancer Center
Track: The Future of Precision Oncology

Thursday
Informing Patient Treatment with Clinicogenomic Data
11:35am - 12:00pm Eastern - June 24, 2021
Elaine R. Mardis, PhD, Nationwide Children's Hospital
Track: The Future of Precision Oncology

Thursday
NCI’s Precision Medicines Initiatives
12:00pm - 12:25pm Eastern - June 24, 2021
Naoko Takebe, MD, PhD, NCI, National Institutes of Health
Track: The Future of Precision Oncology

Thursday
Closing Remarks
12:25pm - 12:35pm Eastern - June 24, 2021
Klaus P. Hoeflich, PhD, Organizer, Nested Bio; Scott W. Lowe, PhD, Organizer, Memorial Sloan Kettering Cancer Center